Apnar Pharma LLP – FDA 483, May 14, 2021
An FDA inspection of AUREX LABORATORIES LLC in East Windsor, NJ, a pharmaceutical manufacturer, revealed significant deficiencies in their written procedures and adherence to quality control responsibilities. Observations included inadequate cleaning and maintenance procedures, failure to follow quality control unit protocols for environmental monitoring and equipment maintenance, and insufficient detail in component sampling procedures. These findings indicate a need for improved procedural documentation and compliance within the firm's manufacturing operations.
ID · 38a30420-1446-41ad-8f09-0485d0d7b4fd
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.